How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol.
about
Hypertriglyceridemia and Cardiovascular Diseases: RevisitedNew drugs for treating dyslipidemia: beyond statinsEffect of HDL-raising drugs on cardiovascular outcomes: a systematic review and meta-regression.Dietary cholesterol affects plasma lipid levels, the intravascular processing of lipoproteins and reverse cholesterol transport without increasing the risk for heart disease.Differential metabolic actions of specific statins: clinical and therapeutic considerationsAn association study between genetic polymorphisms related to lipoprotein-associated phospholipase A(2) and coronary heart disease.Association of G894T eNOS, 4G/5G PAI and T1131C APOA5 polymorphisms with susceptibility to myocardial infarction in MoroccoApolipoprotein A5 gene variants and the risk of coronary heart disease: a case‑control study and meta‑analysis.Current guidelines for high-density lipoprotein cholesterol in therapy and future directions.The injurious effects of hyperinsulinism on blood vessels.Revising the high-density lipoprotein targeting strategies - insights from human and preclinical studies.Pharmacological treatment and therapeutic perspectives of metabolic syndrome.Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.Non-HDL cholesterol vs. apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study.Dysfunctional high-density lipoproteins have distinct composition, diminished anti-inflammatory potential and discriminate acute coronary syndrome from stable coronary artery disease patients.Impact of gender and age on the association of the BUD13-ZNF259 rs964184 polymorphism with coronary heart disease.
P2860
Q26750954-1B1C3C0A-D586-414A-AD54-B8CFAA298648Q26821840-59F77529-761D-4850-ADB1-F6D0C31C9478Q35146964-3B5270C6-24F8-408B-8323-D2C3723B0B8DQ36250301-0F0B510B-948C-430F-A195-3966A4D6BB8DQ36406951-BBA8F326-7968-4446-9BB2-D2381B510D3FQ36603424-8B4B4829-9641-4185-AC2E-17068794AF58Q36870194-05B90010-CCEE-4B35-8CAA-D39593920743Q37693916-2BB7B619-5B82-42FD-B878-6B8767729752Q37702199-AF76D7AF-8D7A-4843-85AE-6896F8255A75Q38172418-E06D6C76-DBB3-41BE-8198-BDBE2E0A5032Q38239205-9748D260-7003-4C45-A6EC-7C82C87EAF48Q38262435-E0C2AC87-06F5-4839-A127-52C763B19C1AQ38546242-048A3D1D-D48A-4DC1-B733-2231E5F3910DQ39383777-EC4958B0-7106-4E01-94CA-54D290C75395Q41260650-6CF975A1-01E4-4981-92E9-395D2BE27FC8Q50019107-70A7658A-D5FC-4BC6-89ED-D24B68E8C38F
P2860
How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
How to control residual cardio ...... : focusing on HDL-cholesterol.
@en
type
label
How to control residual cardio ...... : focusing on HDL-cholesterol.
@en
prefLabel
How to control residual cardio ...... : focusing on HDL-cholesterol.
@en
P1476
How to control residual cardio ...... t: focusing on HDL-cholesterol
@en
P2093
Kwang Kon Koh
Yae Min Park
P356
10.1016/J.IJCARD.2012.03.127
P577
2012-04-12T00:00:00Z